Key Details
Price
$2.45Annual Revenue
$1.50 MAnnual EPS
-$3.75Annual ROE
-101.46%Beta
-0.10Events Calendar
Next earnings date:
Apr 11, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Apr 12, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 25, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
IRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay.
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay.
IRVINE, Calif., Dec. 02, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal Nephrology Dialysis Transplantation.
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal, Nephrology Dialysis Transplantation.
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes.
Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m.
IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™.
Results published in peer-reviewed journal , Clinical Cancer Research Study validates DetermaIO's utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp.
FAQ
- What is the primary business of OncoCyte?
- What is the ticker symbol for OncoCyte?
- Does OncoCyte pay dividends?
- What sector is OncoCyte in?
- What industry is OncoCyte in?
- What country is OncoCyte based in?
- When did OncoCyte go public?
- Is OncoCyte in the S&P 500?
- Is OncoCyte in the NASDAQ 100?
- Is OncoCyte in the Dow Jones?
- When was OncoCyte's last earnings report?
- When does OncoCyte report earnings?
- Should I buy OncoCyte stock now?